User login
Key clinical point: Fecal microbiota transfer (FMT) did not appear to be an effective treatment for irritable bowel syndrome (IBS) symptoms whether administered orally or via colonoscopy, gastroscopy, or a nasojejunal tube, with initial improvements wearing off drastically over time.
Major finding: Despite a significant improvement in the quality-of-life score in the FMT vs control group (mean difference 9.32; P = .0005), the overall change in IBS symptom severity score (P = .67) and the number of respondents considering all routes of administration (P = .19) were not significantly different between treatment arms.
Study details: Findings are from a meta-analysis of eight randomized controlled trials including 472 patients with IBS who received either FMT or autologous transfer/placebo (control group).
Disclosures: This study did not declare any source of funding. The authors declared no conflicts of interest.
Source: Abdelghafar YA et al. Efficacy and safety of fecal microbiota transplant in irritable bowel syndrome: An update based on meta‐analysis of randomized control trials. Health Sci Rep. 2022;5(5):e814 (Sep 12). Doi: 10.1002/hsr2.814
Key clinical point: Fecal microbiota transfer (FMT) did not appear to be an effective treatment for irritable bowel syndrome (IBS) symptoms whether administered orally or via colonoscopy, gastroscopy, or a nasojejunal tube, with initial improvements wearing off drastically over time.
Major finding: Despite a significant improvement in the quality-of-life score in the FMT vs control group (mean difference 9.32; P = .0005), the overall change in IBS symptom severity score (P = .67) and the number of respondents considering all routes of administration (P = .19) were not significantly different between treatment arms.
Study details: Findings are from a meta-analysis of eight randomized controlled trials including 472 patients with IBS who received either FMT or autologous transfer/placebo (control group).
Disclosures: This study did not declare any source of funding. The authors declared no conflicts of interest.
Source: Abdelghafar YA et al. Efficacy and safety of fecal microbiota transplant in irritable bowel syndrome: An update based on meta‐analysis of randomized control trials. Health Sci Rep. 2022;5(5):e814 (Sep 12). Doi: 10.1002/hsr2.814
Key clinical point: Fecal microbiota transfer (FMT) did not appear to be an effective treatment for irritable bowel syndrome (IBS) symptoms whether administered orally or via colonoscopy, gastroscopy, or a nasojejunal tube, with initial improvements wearing off drastically over time.
Major finding: Despite a significant improvement in the quality-of-life score in the FMT vs control group (mean difference 9.32; P = .0005), the overall change in IBS symptom severity score (P = .67) and the number of respondents considering all routes of administration (P = .19) were not significantly different between treatment arms.
Study details: Findings are from a meta-analysis of eight randomized controlled trials including 472 patients with IBS who received either FMT or autologous transfer/placebo (control group).
Disclosures: This study did not declare any source of funding. The authors declared no conflicts of interest.
Source: Abdelghafar YA et al. Efficacy and safety of fecal microbiota transplant in irritable bowel syndrome: An update based on meta‐analysis of randomized control trials. Health Sci Rep. 2022;5(5):e814 (Sep 12). Doi: 10.1002/hsr2.814